Bravintone

Acute and chronic cerebral circulatory insufficiency: acute cerebral infarction, transient ischemia, progressive stroke, post-stroke condition, atherosclerosis of the cerebral arteries, post-traumatic and hypertensive encephalopathy, etc., symptoms of cerebral insufficiency (dizziness, headache, motor disorders, memory disorders, etc.), aphasia, changes in the retina and vascular membranes of the eye (atherosclerotic, angiospastic), degenerative processes in the yellow spot, secondary glaucoma associated with partial vascular thrombosis, hearing loss, Meniere's disease.

Inside, 0.005-0.01 g 3 times a day for a long time. Course — at least 2 months. Improvement is usually observed after 1-2 weeks.

In/in, only in the form of a slow drip infusion. Initial dose of 20 mg/day in 500-1000 ml of infusion solution, then 30 mg/day in 500-1000 ml to 1 mg/kg/day (10-day with a gentle increase of the dose) for 10-14 days before giving injections, the dose is gradually reduced and transferred the patient to oral.

Hypersensitivity, pregnancy, breast-feeding, severe coronary artery disease and severe arrhythmia (solution for infusion).

Low blood pressure, tachycardia, extrasystole.

Increases blood supply to the brain and peripheral tissues, normalizes or lowers systemic blood pressure. Improves the trophism of eye tissues, the course of ophthalmic diseases with partial vascular thrombosis, inhibits the progression of deafness of vascular and toxic origin.

• Correctors of cerebral circulatory disorders

Increases the risk of bleeding on the background of the introduction of heparin.

In a place protected from light, at a temperature not exceeding 25 °C.

Keep out of reach of children.

Do not use after the expiration date indicated on the package.

1 tablet contains 0.005 g of vinpocetine, in a contour cell package of 10 pcs. , in a cardboard pack of 2 packages or in plastic bottles of 50 pcs., in a cardboard pack of 1 bottle.

1 ml of the infusion solution contains 5 mg of vinpocetine, in ampoules of 2 ml, in a contour cell package of 5 ampoules, in a cardboard pack of 2 packages.

N06BX18 Vinpocetine

• G45 Transient transient cerebral ischemic attacks [attacks] and related syndromes
• G45. 0 Vertebrobasilar arterial system syndrome
• G46 Vascular brain syndromes in cerebrovascular diseases
• G93. 4 Encephalopathy, unspecified
• H34 Retinal vascular occlusion
• H34. 0 Transient retinal arterial occlusion
• H34. 8 Other retinal vascular occlusions
• H35. 3 Macular and posterior pole degeneration
• H40 Glaucoma
• H81 Vestibular function disorders
• H81. 0 Meniere's disease
• H83 Other diseases of the inner ear
• H91 Other hearing loss
• I63 Brain infarction
• I67. 4 Hypertensive encephalopathy
• I67. 9 Cerebrovascular disease, unspecified
• I69 Consequences of cerebrovascular diseases
• N95. 1 Menopausal and menopausal conditions in women
• R41. 3. 0* Reduced memory
• R47. 0 Dysphasia and aphasia
• R51 Headache
• T90. 5 Consequences of intracranial trauma